ATE501248T1 - Stabile wässrige systeme mit proteinen - Google Patents

Stabile wässrige systeme mit proteinen

Info

Publication number
ATE501248T1
ATE501248T1 AT06764894T AT06764894T ATE501248T1 AT E501248 T1 ATE501248 T1 AT E501248T1 AT 06764894 T AT06764894 T AT 06764894T AT 06764894 T AT06764894 T AT 06764894T AT E501248 T1 ATE501248 T1 AT E501248T1
Authority
AT
Austria
Prior art keywords
protein
ionisable groups
stabilising
proteins
aqueous systems
Prior art date
Application number
AT06764894T
Other languages
English (en)
Inventor
Jan Jezek
Original Assignee
Arecor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36940697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE501248(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0513653.6A external-priority patent/GB0513653D0/en
Priority claimed from GBGB0610140.6A external-priority patent/GB0610140D0/en
Application filed by Arecor Ltd filed Critical Arecor Ltd
Application granted granted Critical
Publication of ATE501248T1 publication Critical patent/ATE501248T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT06764894T 2005-07-02 2006-07-03 Stabile wässrige systeme mit proteinen ATE501248T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0513653.6A GB0513653D0 (en) 2005-07-02 2005-07-02 Protein stability
GBGB0610140.6A GB0610140D0 (en) 2006-05-22 2006-05-22 Protein stability
PCT/GB2006/002470 WO2007003936A1 (en) 2005-07-02 2006-07-03 Stable aqueous systems comprising proteins

Publications (1)

Publication Number Publication Date
ATE501248T1 true ATE501248T1 (de) 2011-03-15

Family

ID=36940697

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06764894T ATE501248T1 (de) 2005-07-02 2006-07-03 Stabile wässrige systeme mit proteinen

Country Status (8)

Country Link
US (1) US20090148406A1 (de)
EP (3) EP2264162A1 (de)
JP (1) JP5033798B2 (de)
AT (1) ATE501248T1 (de)
CA (1) CA2614006C (de)
DE (1) DE602006020568D1 (de)
DK (1) DK1899462T3 (de)
WO (1) WO2007003936A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0610140D0 (en) 2006-05-22 2006-06-28 Insense Ltd Protein stability
GB2435510A (en) * 2006-02-23 2007-08-29 Mologic Ltd Enzyme detection product and methods
US20090136538A1 (en) * 2006-05-22 2009-05-28 Jan Jezek Stable vaccine formulation
GB0626021D0 (en) 2006-12-29 2007-02-07 Insense Ltd The stabilisation of proteins
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
RU2476442C2 (ru) 2007-03-29 2013-02-27 Эббот Лэборетриз Кристаллические антитела против il-12 человека
JP5273438B2 (ja) * 2007-11-22 2013-08-28 国立大学法人東京農工大学 ペプチド付加生体分子の溶解度計算方法、及びそれを用いたペプチドタグの設計方法と封入体形成防止方法
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CA2904458C (en) * 2007-11-30 2017-07-25 Wolfgang Fraunhofer Protein formulations and methods of making same
CN101952016A (zh) 2007-12-28 2011-01-19 巴克斯特国际公司 重组vwf配方
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
CA2726824A1 (en) * 2008-05-01 2009-11-05 Arecor Limited Protein formulation
EP2113564A1 (de) 2008-05-01 2009-11-04 Arecor Limited Proteinformulierung
EP2341940A1 (de) * 2008-07-16 2011-07-13 Arecor Limited Stabilisierung von proteinen
EP2328607A1 (de) 2008-07-16 2011-06-08 Arecor Limited Stabile formulierung eines therapeutischen proteins
AU2009307648C1 (en) * 2008-10-21 2016-12-08 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
NZ606283A (en) * 2008-11-28 2014-08-29 Abbvie Inc Stable antibody compositions and methods for stabilizing same
NZ595694A (en) * 2009-05-04 2013-09-27 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
CA2726230A1 (en) * 2009-07-16 2010-08-19 Arecor Limited The stabilisation of proteins
WO2011104381A2 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
EP3345615B1 (de) 2010-03-01 2019-10-16 Bayer Healthcare LLC Optimierte monoklonalantikörper gegen tissue factor pathway inhibitor (tfpi)
KR20130086144A (ko) 2010-05-28 2013-07-31 노보 노르디스크 에이/에스 항체 및 보존제를 포함하는 안정한 다중-투여 조성물
MX344727B (es) 2010-11-11 2017-01-05 Abbvie Biotechnology Ltd Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
GB201113880D0 (en) * 2011-08-12 2011-09-28 Archimed Llp Novel compositions
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
WO2014125237A1 (en) 2013-02-12 2014-08-21 Microarray Limited Novel biosensor
FR3014446B1 (fr) 2013-12-10 2017-05-26 Biomerieux Sa Stabilisation de la gdh en solution aqueuse
CN104480095A (zh) * 2014-11-27 2015-04-01 广西大学 一种酶活力稳定的液态木瓜蛋白酶制剂
US11173197B2 (en) 2015-07-07 2021-11-16 Bluewillow Biologics, Inc. Methods and compositions for nanoemulsion vaccine formulations
US20170007694A1 (en) * 2015-07-07 2017-01-12 Nanobio Corporation Methods and compositions for the stabilization of proteins
DK3347031T3 (da) 2015-09-11 2021-04-26 Nutrition & Biosciences Usa 1 Llc Sammensætning, der omfatter et protein og en polyalkoxyfedtforbindelse
US10301428B2 (en) 2015-09-11 2019-05-28 Dow Global Technologies Llc Polyalkoxy fatty compound

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3051627A (en) 1960-08-18 1962-08-28 Armour Pharma Stabilized chymotrypsin solution
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
CA2062659A1 (en) * 1991-03-12 1992-09-13 Yasutaka Igari Composition for sustained-release of erythropoietin
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
IT1247946B (it) 1991-05-17 1995-01-05 Instrumentation Lab Srl Stabilizzazione in forma liquida dell'enzima urato ossidasi
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
CN1222315C (zh) 1996-12-24 2005-10-12 拜奥根有限公司 稳定的液体干扰素制剂
WO2002013860A1 (fr) * 2000-08-11 2002-02-21 Chugai Seiyaku Kabushiki Kaisha Preparations stabilisees contenant un anticorps
JP2002125693A (ja) * 2000-10-19 2002-05-08 Toyobo Co Ltd 無細胞タンパク質合成用細胞抽出液組成物
RU2323002C2 (ru) 2001-07-26 2008-04-27 Чирон Срл. Вакцины, содержащие алюминиевые адъюванты и гистидин
WO2003021258A1 (en) * 2001-08-30 2003-03-13 Board Of Regents, The University Of Texas System Ensemble-based analysis of the ph-dependence of stability of proteins
EP1429739A1 (de) * 2001-09-21 2004-06-23 Egalet A/S Polymer-freigabe-system
AU2002351756A1 (en) * 2001-12-21 2003-07-15 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
GB0202633D0 (en) * 2002-02-05 2002-03-20 Delta Biotechnology Ltd Stabilization of protein preparations
JP5000848B2 (ja) * 2002-05-21 2012-08-15 第一三共株式会社 グレリン含有医薬組成物
JP2006523609A (ja) * 2002-12-31 2006-10-19 アルタス ファーマシューティカルズ インコーポレイテッド タンパク質結晶およびイオン性ポリマーの複合体
CA2528465A1 (en) * 2003-06-09 2005-01-20 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of growth hormone
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US20050281879A1 (en) * 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation

Also Published As

Publication number Publication date
EP1899462B1 (de) 2011-03-09
EP1899462A1 (de) 2008-03-19
EP2264162A1 (de) 2010-12-22
EP2264161A1 (de) 2010-12-22
WO2007003936A1 (en) 2007-01-11
DE602006020568D1 (de) 2011-04-21
JP2008544977A (ja) 2008-12-11
JP5033798B2 (ja) 2012-09-26
CA2614006C (en) 2014-11-04
DK1899462T3 (da) 2011-06-06
US20090148406A1 (en) 2009-06-11
CA2614006A1 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
ATE501248T1 (de) Stabile wässrige systeme mit proteinen
DE60105362D1 (de) Wässrige kosmetische gele
BRPI0410616A (pt) xampu condicionador
BR0211404A (pt) Aminas, ácidos, aminoácidos e tioéter ácidos substituìdos com perfluoroalquil
BRPI0512396A (pt) polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
UA87506C2 (ru) Применение электролита как стабилизатора ингибитора
GB2446992A (en) Pathogen-controlling products
TR199901968T2 (xx) Sabit s�v� interferon form�lleri.
ATE225842T1 (de) Flüssige enzymzubereitung und ihre verwendung
RS52706B (en) FORMATION OF DRIED RECONSTITUTED VESICULES FOR PHARMACEUTICAL APPLICATION
BR0014486A (pt) Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
ATE536369T1 (de) Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung
RS50966B (sr) Agonisti pyy i njihova upotreba
ATE512121T1 (de) Verwendung von cersalzen zur inhibierung der abscheidung von mangan in wassersystemen
ATE551381T1 (de) Verfahren zur herstellung von hochkonzentrierte pelletierte additivkonzentrate für polymer
BR0014199A (pt) Derivados de bifenila como inibidores de nhe-3
DE60229958D1 (de) Polymerstabilisierte proteinasen
ATE461276T1 (de) Enzymstabilisierung
DE60129137D1 (de) Modulierung durch il-tif/interleukin-21
BRPI0608020A2 (pt) processo para a produção de uma composição contendo proteìna de soja e composição contendo proteìna de soja
DK1517966T3 (da) Sammensætning på basis af vandig maling, især en lasur eller lak og en kolloid, vandig dispersion af cerium
TR200301248A2 (tr) Antibiyotik Aktiviteye Sahip Olan Farmasotik Kompozisyonlar.
EA200801875A1 (ru) Антагонист cd 80
DE50005906D1 (de) Wässrige kunststoff-dispersionen mit erhöhter stabilität
BRPI0409564A (pt) sistema estabilizador para polìmeros halogenados

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1899462

Country of ref document: EP